Related Experiment Videos
Intraperitoneal therapy with interferon-alpha in CAPD patients with relapsing bacterial peritonitis
S Carozzi1, M G Nasini, C Schelotto
1Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy.
Abstract:
In CAPD patients with relapsing bacterial peritonitis who do not benefit from intraperitoneal therapy with IgG (IgG nonresponders), the authors demonstrated that peritoneal macrophages are deficient in IgG Fc receptors (FcR) and, therefore, unable to kill bacteria, independent of the levels of the opsonic molecule IgG in the peritoneal dialysis effluent (PDE). Because previous studies showed that interferon-alpha (IFN-alpha) is able to increase in vitro the number of PM0 IgG FcR in CAPD patients with relapsing bacterial peritonitis, the authors studied the in vivo effects of IP administration of IFN-alpha (1,000 IU daily in the overnight exchange for 12 months) on: PM0 superoxide generation; PM0 bacterial killing; PM0 IgG FcR; the number of bacteria in the PM0 cytoplasm; and peritonitis relapses in these patients. By the 10th day, IFN-alpha induced a progressive rise in all of the previously depressed PM0 functions tested, the disappearance of bacteria from the PM0 cytoplasm, and no further episodes of bacterial peritonitis were detected during 12 months. These data indicate that IFN-alpha may represent a useful tool for preventing infections in CAPD patients with relapsing bacterial peritonitis.
Insights
Interferon-alpha (IFN-alpha) therapy improved peritoneal macrophage function in patients with relapsing bacterial peritonitis. This treatment prevented further infection episodes in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Area of Science:
- Immunology
- Nephrology
- Infectious Diseases
Background:
- Continuous ambulatory peritoneal dialysis (CAPD) patients with relapsing bacterial peritonitis may not respond to immunoglobulin G (IgG) therapy.
- These patients exhibit peritoneal macrophages deficient in IgG Fc receptors (FcR), impairing bacterial killing capacity.
Purpose of the Study:
- To investigate the in vivo efficacy of intraperitoneal (IP) interferon-alpha (IFN-alpha) in treating CAPD patients with relapsing bacterial peritonitis.
- To assess the impact of IFN-alpha on peritoneal macrophage (PM0) function, bacterial clearance, and peritonitis recurrence.
Main Methods:
- IP administration of IFN-alpha (1,000 IU daily for 12 months) in CAPD patients with relapsing bacterial peritonitis.
- Evaluation of PM0 superoxide generation, bacterial killing, IgG FcR expression, intracellular bacterial counts, and peritonitis relapse rates.
Main Results:
- IFN-alpha treatment significantly enhanced PM0 superoxide generation and bacterial killing capacity within 10 days.
- The therapy led to increased PM0 IgG FcR expression and reduced intracellular bacteria.
- No peritonitis relapses were observed in patients during the 12-month treatment period.
Conclusions:
- IP IFN-alpha effectively restores peritoneal macrophage function in CAPD patients with relapsing bacterial peritonitis.
- IFN-alpha demonstrates potential as a therapeutic agent for preventing recurrent infections in this patient population.